Friday, 22 January 2021

Aditya Puri joins Strides Group as Advisor, Director of associate Company, Stelis

08 January 2021 | News

Puri’s appointment to the Stelis Board comes at an exciting juncture for the company as it transitions from its incubation phase to a consolidation and growth phase to establish itself as a partner of choice globally with the aim of bringing world-class treatments at affordable costs to patients in both emerging and developed markets   

Strides Pharma Science Limited is pleased to announce that eminent corporate doyen Aditya Puri joins the Strides Group as an Advisor and also will be a Director of its associate Company, Stelis Biopharma.

Recognised as a stalwart of the Indian banking and financial services industry, Puri was the iconic founder-Managing Director and Chief Executive Officer of HDFC Bank from its inception in 1994 until his retirement from the position in October 2020. Prior to setting up HDFC Bank, he was Chief Executive Officer of Citibank Malaysia with nearly two decades of overall banking experience across markets with Citibank. Puri has been conferred with several prestigious awards, accolades and titles for his exceptional contribution to Indian industry.

Puri’s appointment to the Stelis Board comes at an exciting juncture for the company as it transitions from its incubation phase to a consolidation and growth phase to establish itself as a partner of choice globally with the aim of bringing world-class treatments at affordable costs to patients in both emerging and developed markets.

Commenting on the development, Puri said: “The Group’s established parentage, global success and headstart in terms of basic infrastructure, gives me the opportunity to be involved in and guide Stelis and other Group endeavours in their exciting growth story.”

Commenting on the development, Arun Kumar, Founder & Chairman of the Board, Strides, said: “With Stelis poised for its next leg of growth, this is the right time to expand the Board, and ensure robust guidance and governance by the best possible industry minds. I look forward to working with Aditya and leveraging his expertise to take Stelis to new heights.”

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account






Survey Box

Should we be cautious of viewing COVID-19 vaccine as silver bullet?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls